Lumibird Sa · EURONEXT:LBIRD
Lumibird Sa — Investor Presentation (January 2021)
22 slides from Lumibird Sa's investor presentation, Jan 25, 2021
Slide 1: Lighting the Path
LIGHTING THE PATH a N \ \ = O = % Q.. = ao) (gv) oO) \ oe ? one Mian
Slide 2: Presenters
es ( Marc LE FLOHIC Jean-Marc GENDRE Aude NOMBLOT-GOURHAND Pierre VALLALTA Chairman Deputy CEO Secretary General - CFO Advisor Strategy & Finance
Slide 3: Agenda
1 2020 revenues: resilience faced with the crisis 2 LUMIBIRD today 3 Our markets 4. 2023 strategy and objectives
Slide 4: 2020: Resilience faced with the crisis
Slide 5: 2020 revenue growth
2020 revenue growth in line with expectations €146.4m €126.7m €110.7m Defense / Space Industrial & Scientific §-4.1% €25.2m 71.4 Photonics 9 Lidar Sensors tra8. sd €22.0m 39.3 2019 2020 Mmmm Photonics 2020 proforma MEE Medical Proforma: including Ellex at January 1, 2020 * Good resilience for the hi
Slide 6: Lumibird today
LUMIBIRD TODAY
Slide 7: Offering innovative laser solutions
Offering innovative laser solutions Lasers are crucial for LUMIBIRD has deep developin expertise in laser technologies to deliver tomorrow's * ° . technologies solutions aligned with —_ ~ fequirements |_» Power -—e Photonics: 4th revolution |—e Range focused on sensors le Medical: continuous innovat
Slide 8: A leading European laser company with a global presence
A leading European laser company with a glo bal presence Lumibird €146.4m aeue 2020 pro forma revenues its solutions to Eoin acd 82% 800 +110 Ws. 20 pro uction an Percentage 2020 pro forma countries <on & 1 H average workforce 4 - development sites of export Medical €77.9m | Photonics €68.5m Medical
Slide 9: Medical and Photonics
MEDICAL Designing, manufacturing and selling medical equipment eRe | ® Ophthalmological diagnostic ultrasounds Interventional Dry eye e—— ultrasound » OPTOTEK MEDICAL Brand® PHOTONICS Designing, manufacturing and selling lasers and laser systems Lasers and e————_|_ High-power sensor lasers amplifier
Slide 10: Proforma 2020 revenues for each region
Proforma 2020 revenues for each region =m Medical mmm Photonics
Slide 11: Track record of profitable growth and successful integrations
Track record of profitable growth and successful integrations bad 146. 126.7 4 ‘4 oo. 110 ae Total . otal” 100.7 7 organic §=—91 6% 85.1 growth Total ; of externa| 17.2 growth 72" 2016 2017 2018 2019 2020 Proforma a, ve al a 2020 conso Pees 5 HALO Photonics ee | ql: : =O ellex
Slide 12: Impact of growth on profitability
Impact of growth on profitability Improvement in profitability since 2016 Ql; onracr Eanes Cc) 100.7 110.7 Vv ; Critical mass / margins Vv impact on Product range V4 VS V4 v4 oe WV A v X4.0* Impact on POLUETEE Optimization of support services WV WV JS 2016 2017 2018 2019 mmm Revenues =—=—Income from
Slide 13: Our markets
OUR MARKETS
Slide 14: Laser markets
LASER MARKETS | S 2 6 bn FORECASTS: GLOBAL LASER MARKET by 2025 DEVELOPMENT (Sbn) Lumibird’s markets Displays 27% Optical Storage 3% 1% 25.9 23.8 Communications — 15.0 + R&D 4 31% oa +9.6% CAGR 20-25 Communications 23% Printing KW Materials Photolith <1% Proc + 201 2020 2021 2022 2023 2024 2025 Mate
Slide 15: Drivers: Lidar and sensors
Drivers Sensors market is the 4‘ photonic revolution (after D' telecoms and materials processing / cutting) Autonomous mobility (transport, logistics, etc.) Machine intelligence and vision (3D scanning, automation) Renewable energies (wind lidar, preventive maintenance) LUMIBIRD positioning Laser te
Slide 16: Defense / Space
Defense / Space Drivers . Defense: technological race: Reduction of energy consumption and bulk and increase in efficiency Development of new sensors with increased sensitivity, range and resolution Technical development of laser weapons Desire for European independence in relation to the US * Space
Slide 17: Medical
Medical Drivers ° Aging population ° Increased access to healthcare * Evolution of treatments for pathologies (less invasive, Al, etc.) LUMIBIRD positioning Development and manufacturing of medical systems for ophthalmological and point-of-care diagnosis and treatment Clients: * Practitioners and ho
Slide 18: 2023 strategy and objectives
Slide 19: 2023 objectives
2023 objectives Double revenues Revenues X2 -—e Organic growth: 8% to 10% per year by 2023 '—e External growth: focused on the buoyant Lidar, Defense and Medical markets Increase | profitability = 20 to 25% EBITDA '—e Integration, synergies, industrialization, verticalization Recruiting, supporting
Slide 20: Doubling revenues
DOUBLING REVENUES ORGANIC GROWTH EXTERNAL GROWTH Supported by market drivers, our Acquisition of market shares and technological innovations and our technologies acquisitions Medical: consolidation of sales for the Medical: acquisition of key existing product portfolio across all ophthalmology techn
Slide 21: Procurement performance
Procurement performance Definition of new procurement organization (central / local responsibilities) Rationalization of “regular” suppliers with referencing and negotiation of contracts Supply chain excellence Operating model optimization Sourcing ® Production ® Distribution IMPROVING PROFITABILITY
Slide 22: Shareholding structure
Shareholding structure Public Esira/Eurodyne 48.07 % 51.93 % 22